chufangao/CTO huggingface dataset:
Clinical trial NCT03608358: Safety and Efficacy of Dapagliflozin in Asian T2DM Subjects With Inadequate Glycemic Control on Metformin/Saxagliptin
Official title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Asian Subjects With T2DM and Inadequate Glycemic Control on Metformin and Saxagliptin (DS Navigation)
Sponsor: AstraZeneca (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Sponsor decided to stop commercialization of QTERNMet/Qtrilmet and to stop all related ongoing activities/studies for business reasons.
Enrollment: 41.0 (ACTUAL)
Number of arms: 3.0
Start date: 2019-02-27
Primary completion date: 2020-08-04
Completion date: 2020-08-04
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal.~All request will be evaluated as per the AZ disclosure commitment:~https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
IPD time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Clinical trial NCT04205136: Spironolactone to Improve Apnea and Cardiovascular Markers in Obstructive Sleep Apnea Patients
Official title: Spironolactone to Improve Apnea and Cardiovascular Markers in Obstructive Sleep Apnea Patients With Cardiovascular Disease Who Are Non-Adherent With Positive Airway Pressure: A Randomized Placebo-Controlled Pilot Trial
Sponsor: University of Michigan (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: Was on hold due to Covid then we were not able to initiate the funding again after such a long hold and loss of team members.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-03-31
Primary completion date: 2023-04-30
Completion date: 2023-04-30
Plan to share individual participant data: NO
IPD sharing description: The study team does not have plans to actively share data, however, they are open to collaboration following contact with the investigator.
Clinical trial NCT04286594: A Clinical Trial of a Hemp-Derived Cannabidiol Product for Anxiety
Official title: A Clinical Trial of a Hemp-Derived Cannabidiol Product for Anxiety
Sponsor: Mclean Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Terminated by sponsor
Enrollment: 15.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-02-01
Primary completion date: 2023-08-24
Completion date: 2023-08-24
Plan to share individual participant data: UNDECIDED
Clinical trial NCT04369469: Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia
Official title: A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared With Best Supportive Care in Patients With COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome
Sponsor: Alexion Pharmaceuticals, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Met futility bar at interim analysis
Enrollment: 202.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-05-10
Primary completion date: 2021-02-08
Completion date: 2021-04-08
Baseline population: The ITT Population consisted of all randomized participants. Participants were analyzed as randomized.
Limitations and caveats: Enrollment of participants was paused on 13-Jan-2021. At that time, 202 participants had been randomized. An interim analysis for efficacy and futility was conducted on data from the first 122 participants who completed the Primary Evaluation Period. The analysis showed that the study met the prespecified stopping criteria for futility. After review of all participant data, Alexion terminated the study on 01-Sep-2021.
Plan to share individual participant data: YES
IPD sharing description: Alexion has a public commitment to allow requests for access to study data and will be supplying a protocol, CSR, and plain language summaries.
Clinical trial NCT05676697: PI3K Delta Inhibitor in Relapsed / Refractory Autoimmune Hemolytic Anemia Patients After Receiving Two or More Lines of Therapy
Official title: Safety and Efficacy Study of PI3K Delta Inhibitor in Relapsed / Refractory Autoimmune Hemolytic Anemia Patients After Receiving Two or More Lines of Therapy
Sponsor: Institute of Hematology & Blood Diseases Hospital, China (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Did not meet the anticipated outcome.
Enrollment: 4.0 (ACTUAL)
Number of arms: 1.0
Start date: 2023-01-13
Primary completion date: 2024-01-31
Completion date: 2024-02-06
Plan to share individual participant data: NO
Clinical trial NCT03709550: Enzalutamide and Decitabine in Treating Patients With Metastatic Castration Resistant Prostate Cancer
Official title: Phase Ib/II Study of Enzalutamide With Decitabine, a DNA Hypomethylating Agent, in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Sponsor: Roswell Park Cancer Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: WITHDRAWN 
Why stopped: lack of funding
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-04-15
Primary completion date: 2023-04-15
Completion date: 2024-04-15
Clinical trial NCT04432831: A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Diabetic Macular Edema
Official title: A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Patients With Diabetic Macular Edema
Acronym: Rhone-X
Sponsor: Hoffmann-La Roche (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 1479.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-08-05
Primary completion date: 2023-10-11
Completion date: 2023-10-11
Plan to share individual participant data: YES
IPD sharing description: For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
Clinical trial NCT05112419: A Study to Assess Zibotentan Pharmacokinetics in Participants With Moderate Hepatic and Moderate Renal Impairment
Official title: A Single Dose, Non-Randomised, Open-Label, Parallel-Group Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Zibotentan in Healthy Participants Compared to Participants With Moderate Hepatic and Moderate Renal Impairment
Sponsor: AstraZeneca (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 12.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-11-10
Primary completion date: 2021-12-15
Completion date: 2021-12-15
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment:~https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.~Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
IPD time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Clinical trial NCT01850004: Open-Label Study Evaluating Dasatinib Therapy Discontinuation in Patients With Chronic Phase Chronic Myeloid Leukemia With Stable Complete Molecular Response
Official title: Open-Label Single Arm Phase 2 Study Evaluating Dasatinib Therapy Discontinuation In Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML) With Stable Complete Molecular Response (CMR) DASFREE
Acronym: DASFREE
Sponsor: Bristol-Myers Squibb (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 84.0 (ACTUAL)
Number of arms: 1.0
Start date: 2014-01-22
Primary completion date: 2017-09-20
Completion date: 2021-10-08
Clinical trial NCT03251924: A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors
Official title: A Phase 1/2 Dose Escalation and Combination Cohort Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Efficacy of BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors
Sponsor: Bristol-Myers Squibb (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Study CA021-002 was terminated because the Sponsor discontinued further development of BMS-986226 due to a change in business objectives. The decision for the study closure was not related to any safety concerns associated with BMS-986226.
Enrollment: 80.0 (ACTUAL)
Number of arms: 3.0
Start date: 2017-09-01
Primary completion date: 2021-12-20
Completion date: 2021-12-20
Limitations and caveats: Study CA021002 was terminated because the Sponsor discontinued further development of BMS-986226. The decision for the study closure was not related to any safety concerns associated with BMS-986226.
Clinical trial NCT04969861: BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36)
Official title: A Phase 2/3, Randomized, Open-label Study to Compare Bempegaldesleukin Combined With Pembrolizumab Versus Pembrolizumab Alone in First-Line Treatment of Patients With Metastatic or Recurrent Head and Neck Squamous-Cell Carcinoma With PD-L1 Expressing Tumors (PROPEL-36)
Sponsor: Nektar Therapeutics (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: TERMINATED 
Why stopped: Nektar Therapeutics made the decision to discontinue the bempegaldesleukin program based on three negative studies. SFJ Pharmaceuticals, Inc. and Nektar Therapeutics, in consultation with the study IDMC, have decided to discontinue PROPEL-36.
Enrollment: 1.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-03-09
Primary completion date: 2022-04-22
Completion date: 2022-04-22
Baseline population: Following the Sponsor's decision to end the trial, treatment was discontinued after one patient received 2 cycles of BEMPEG + Pembrolizumab
Clinical trial NCT04243824: Ga-68 MAA Distribution in PAE Patients
Official title: The Evaluation of Ga-68 MAA Distribution in Prostatic Artery Embolization Patients
Sponsor: University of North Carolina, Chapel Hill (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: WITHDRAWN 
Why stopped: Lack of funding
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-05-31
Primary completion date: 2022-05-31
Completion date: 2022-05-31
Plan to share individual participant data: YES
IPD sharing description: Deidentified individual data that supports the results will be shared beginning 9 to 36 months following publication provided the investigator who proposes to use the data has approval from an Institutional Review Board (IRB), Independent Ethics Committee (IEC), or Research Ethics Board (REB), as applicable, and executes a data use/sharing agreement with UNC.
IPD time frame: 9 to 36 months following publication
IPD access criteria: The investigator who proposes to use the data has approval from an IRB, IEC, or REB, as applicable, and an executed data use/sharing agreement with UNC.
Clinical trial NCT03185013: REVEAL 1 (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)
Official title: A Prospective, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of VGX-3100 Delivered Intramuscularly Followed by Electroporation With CELLECTRA™-5PSP for the Treatment of HPV-16 and/or HPV-18 Related High Grade Squamous Intraepithelial Lesion (HSIL) of the Cervix
Acronym: REVEAL 1
Sponsor: Inovio Pharmaceuticals (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 201.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-06-28
Primary completion date: 2020-07-08
Completion date: 2021-04-06
Baseline population: ITT population included all participants who were randomized.
Clinical trial NCT04354441: Effect of Hydroxychloroquine in COVID-19 Positive Pregnant Women
Official title: Randomized Trial Evaluating Effect of Outpatient Hydroxychloroquine on Reducing Hospital Admissions in Pregnant Women With SARS-CoV-2 Infection: HyPreC Trial
Acronym: HyPreC
Sponsor: Sir Mortimer B. Davis - Jewish General Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Not started
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-05-31
Primary completion date: 2020-05-31
Completion date: 2020-05-31
Clinical trial NCT03042312: Lutetium-177 (Lu177) Prostate-Specific Antigen (PSMA)-Directed EndoRadiotherapy
Official title: PSMA-directed endoRadiothErapy of Castration-reSISTant Prostate Cancer (RESIST-PC). A Phase II Clinical Trial
Acronym: RESIST-PC
Sponsor: Endocyte (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Recruitment was stopped before the target sample size was achieved.
Enrollment: 71.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-07-12
Primary completion date: 2020-01-15
Completion date: 2020-01-15
Limitations and caveats: The study began on 05-Jul-17 as an Investigator Initiated Trial and sponsorship was transferred to Endocyte on 01-Jun-18. Recruitment was stopped before the target sample size was achieved based on strategic considerations.
Plan to share individual participant data: NO
Clinical trial NCT02541045: Clinical Trial to Evaluate the Efficacy of Metadoxine as a Therapy for Patients With Non-alcoholic Steatohepatitis
Official title: Clinical Trial to Evaluate the Efficacy of Metadoxine as a Therapy for Patients With Non-alcoholic Steatohepatitis
Sponsor: Hospital General de Mexico (OTHER_GOV)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: lack of resources to finance the project
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2015-08-31
Primary completion date: 2024-03-31
Completion date: 2024-03-31
Clinical trial NCT02626455: Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)
Official title: A Phase III, Randomized, Double-blind, Controlled Multicenter Study of Intravenous PI3K Inhibitor Copanlisib in Combination With Standard Immunochemotherapy Versus Standard Immunochemotherapy in Patients With Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)
Acronym: CHRONOS-4
Sponsor: Bayer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: The study did not meet the primary endpoint. The addition of copanlisib to standard immunochemo therapy did not improve progression-free survival compared to the control arm. Base on the study results, company decided to terminate the study.
Enrollment: 547.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-01-06
Primary completion date: 2023-09-15
Completion date: 2023-11-10
Plan to share individual participant data: NO
IPD sharing description: Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA Principles for responsible clinical trial data sharing. This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014.~Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.
Clinical trial NCT04414631: Conestat Alfa in the Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19
Official title: Recombinant Human C1 Esterase Inhibitor (Conestat Alfa) in the Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19: a Randomized, Parallel-group, Open-label, Multi-center Pilot Trial (PROTECT-COVID-19).
Sponsor: University Hospital, Basel, Switzerland (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Aim to enroll 120 patients deemed not sufficient to show a difference in the primary outcome measure. Standard of care treatment recently changed in Switzerland adding further heterogeneity to trial population when including future participants.
Enrollment: 80.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-08-06
Primary completion date: 2021-09-15
Completion date: 2021-09-15
Clinical trial NCT04632940: Phase 3 Trial of Pamrevlumab or Placebo in Combination With Systemic Corticosteroids in Participants With Ambulatory DMD
Official title: A Phase 3, Randomized, Double-Blind, Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids in Ambulatory Subjects With Duchenne Muscular Dystrophy (DMD)
Acronym: LELANTOS-2
Sponsor: FibroGen (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Study did not meet its primary endpoint.
Enrollment: 73.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-03-03
Primary completion date: 2023-06-12
Completion date: 2023-12-14
Baseline population: The intent-to-treat (ITT) set included all randomized participants.
Plan to share individual participant data: UNDECIDED
Clinical trial NCT04661033: Safety, Pharmacokinetics, and Efficacy of Subcutaneous Isatuximab in Adults With Warm Autoimmune Hemolytic Anemia (wAIHA)
Official title: A Multicenter, Open-label, Non-randomized, Phase 1b/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Subcutaneous Isatuximab in Adults With Warm Autoimmune Hemolytic Anemia
Sponsor: Sanofi (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Study discontinuation based on strategic sponsor decision; not driven by any safety concerns.
Enrollment: 8.0 (ACTUAL)
Number of arms: 4.0
Start date: 2021-09-09
Primary completion date: 2023-06-26
Completion date: 2023-06-26
Baseline population: Safety population included all participants exposed to the investigational medicinal product (IMP) (regardless of the amount of treatment administered). The study was prematurely terminated based on strategic sponsor decision during Part A; not driven by any safety concerns, hence Part B was not conducted, and no analysis was performed.
Limitations and caveats: The study was prematurely terminated based on strategic sponsor decision during Part A; not driven by any safety concerns, hence Part B was not conducted, and no analysis was performed.
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Clinical trial NCT01610206: A Randomized Study of Safety and Efficacy of Pazopanib and Gemcitabine in Persistent or Relapsed Ovarian Cancer
Official title: A Randomized Open Label Phase II Study of Weekly Gemcitabine Plus Pazopanib Versus Weekly Gemcitabine Alone in the Treatment of Patients With Persistent or Relapsed Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma
Sponsor: University of Virginia (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 148.0 (ACTUAL)
Number of arms: 2.0
Start date: 2012-09-30
Primary completion date: 2018-06-01
Completion date: 2020-12-31
Baseline population: All eligible and randomized participants who received study treatment.
Limitations and caveats: Our study is limited by lack of placebo control, independent pathology and radiologic review, and correlative science. We did not collect data regarding quality of life, and the study was performed in an unselected patient population.
Clinical trial NCT04920916: Safety and Efficacy of Dupilumab for Treatment of Hospitalized COVID-19 Patients
Official title: Safety and Efficacy of the Treatment of Hospitalized Patients With COVID 19 Infection With an Inhibitor of IL-4 and IL-13 Signaling: A Phase IIa Trial
Acronym: SafeDrop
Sponsor: University of Virginia (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 40.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-05-25
Primary completion date: 2023-04-18
Completion date: 2023-04-18
Limitations and caveats: This was a small study, designed as an early phase trial. Limitations included lack of achievement of the primary endpoint and the wide confidence intervals in the survival benefit of dupilumab at day 60. Additional limitations included unequal gender distribution between groups (also due to small sample size), patients were almost exclusively infected by the Delta variant of SARS CoV-2 and a higher-than-expected overall mortality rate.
Plan to share individual participant data: YES
Clinical trial NCT03745586: Giant Cell Arteritis Treatment With Ultra-short Glucocorticoids and Tocilizumab
Official title: Giant Cell Arteritis Treatment With Ultra-short Glucocorticoids and Tocilizumab
Acronym: GUSTO
Sponsor: Insel Gruppe AG, University Hospital Bern (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: COMPLETED 
Enrollment: 18.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-12-01
Primary completion date: 2020-11-30
Completion date: 2021-03-01
Plan to share individual participant data: UNDECIDED
Clinical trial NCT04759846: Hepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF Melanoma
Official title: 'An Open Label, Multicentre, Phase I Study to Evaluate the Impact of Moderate and Severe Hepatic Impairments on the Pharmacokinetics and Safety of Encorafenib in Combination With Binimetinib in Adult Patients With Unresectable or Metastatic BRAF V600-mutant Solid Tumors'.
Sponsor: Pierre Fabre Medicament (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: no recruitment
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2021-01-21
Primary completion date: 2023-05-31
Completion date: 2023-05-31
Plan to share individual participant data: NO